Home
 /
Papers
 /
Biochemistry
 /
A small molecule inhibitor of NVL suppresses tumor growth by blocking ribosome biogenesis
Preprint
Open access
Top 1% · Validated by QED

A small molecule inhibitor of NVL suppresses tumor growth by blocking ribosome biogenesis

Holly H. Guo, Ye Tao, Victor E. Cruz +12 more
August 2025
 ·
bioRxiv
 ·
DOI 
10.1101/2025.07.31.667081
99
%
QED Score
QED Impressions

By developing first-in-class inhibitors of the ribosome assembly factor NVL, this work validates a decades-long hypothesis that cancer's dependence on ribosome biogenesis is a targetable vulnerability—and proves it can be exploited without genotoxicity.

Run full QED analysis
Read paper
Save

QED claims analysis

Summary

The dibenzothiazepinone MM17 and its bioavailable analog MM927 selectively inhibit the AAA+ ATPase NVL by binding to specific sites within the hexameric assembly, thereby blocking 60S ribosomal subunit maturation in the nucleolus and inducing cell cycle arrest through both p53-dependent and p53-independent pathways without causing DNA damage, ultimately suppressing tumor growth in mouse models of colorectal cancer and leukemia without observable toxicity.

See full analysis
Main Claim 1 –

NVL Is the Direct Molecular Target of MM17

Supporting evidence

  • MM17 Directly Binds NVL; Resistance Mutations Reduce Binding
  • MM17 Binds Two NVL Hexamer Sites Near Resistance Mutations
Main Claim 2 –

MM17 Blocks Nucleolar 60S Ribosomal Subunit Biogenesis

Supporting evidence

  • MM17 Phenocopies NVL Depletion in Polysome Profiling Signatures
Main Claim 3 –

NVL Inhibition Triggers p53-Dependent and p53-Independent Cell Cycle Arrest

Supporting evidence

  • TP53 and CDKN1A Knockouts Most Strongly Confer MM17 Resistance
  • MM17 Activates p53 via the Impaired Ribosome Biogenesis Checkpoint
Main Claim 4 –

MM927 Suppresses Mouse Tumor Growth Without Observable Toxicity

Supporting evidence

  • MM927 Is a Bioavailable, More Potent MM17 Analog
  • NVL Inhibition Shows Cross-Cancer Efficacy with Cell-Type-Specific Responses
  • NVL Inhibitors Block Ribosome Biogenesis Without Inducing DNA Damage
  • MM17 Activity Profiles Correlate with 5-FU and Oxaliplatin

Abstract

A longstanding hypothesis, stemming from the enlarged nucleoli typical of cancer cells, posits ribosome production as a selective cancer liability. Certain genotoxic chemotherapies work partly by disrupting ribosome biogenesis, highlighting the need for selective inhibitors of this pathway. Using forward genetics, we identified mutations in the essential 60S ribosomal subunit assembly factor NVL that confer resistance to MM17, a dibenzothiazepinone with anticancer activity. Cryo-EM reconstructions of the NVL hexameric assembly reveal two MM17 docking sites adjacent to resistance mutations. NVL inhibition by MM17 arrests 60S biogenesis in the nucleolus and induces cell cycle arrest or apoptosis through both MDM2/p53-dependent and p53-independent pathways, without causing DNA damage. A bioavailable analog, MM927, suppresses tumor growth in mouse models of leukemia and colorectal cancer without observable toxicity. These findings establish NVL inhibitors as a promising new class of targeted therapeutics and validate ribosome biogenesis as a cancer-specific vulnerability.

Related papers

How the QED Score works

QED Score is an AI-based quality metric for life science research. It rates each paper on two dimensions: originality (is the finding new and important?) and validity (does the evidence support the claims?). Author names and affiliations are removed before scoring. Each manuscript is broken down into its claims and the experiments behind them, and specialized AI agents then examine those claims for statistical rigor, consistency across figures, and contradictions with the existing literature. A verification layer re-checks every issue they flag. Scores are percentile ranks against all papers in the corpus. In a blinded study of papers where QED Score and journal rank disagreed, domain experts sided with QED Score in 75% of cases.
Read the methodology

Free access for academic researchers

Create your free QED account to validate your research, strengthen grant proposals, and uncover scientific insights.
We've sent you an access link.
Please check your inbox.

Didn't get your email? Check your spam folder or reach out to info@qedscience.com

Oops! Something went wrong while submitting the form.
Looking for QED for pharma, biotech or life science organizations?